Theoretical stack · Weight Loss & Body Composition

GLP-1 + Amylin Combination Therapy

Tirzepatide + Pramlintide + Cagrilintide

Moderate–Strong

Theoretical educational discussion

This page summarizes a peptide combination as discussed in the research and user communities. It does not constitute medical advice, dosing recommendations, or instructions for personal use. Combination-specific human RCT evidence is generally absent for these stacks; per-compound evidence does not transfer additively to combinations.

Decisions about peptide therapy require an appropriately licensed clinician. We do not sell peptides.

At a glance

The pharmacologic logic behind CagriSema and the broader incretin-plus-amylin direction in modern obesity medicine: pair the GLP-1 (or GLP-1/GIP) appetite-suppression mechanism with amylin's complementary satiety and gastric-emptying biology.

Compounds in the stack

Each compound's role in the combination, with link to its full peptide page for the underlying research.

Tirzepatide
Dual GIP/GLP-1 receptor agonist; ~21% weight loss in SURMOUNT-1 — currently the deepest FDA-approved obesity agent
FDA-approved · Mounjaro / Zepbound
Pramlintide
FDA-approved synthetic amylin analog (Symlin); the longest-validated amylin-pathway therapy
FDA-approved · TID injection
Cagrilintide
Long-acting amylin analog being developed by Novo Nordisk as a once-weekly amylin agonist for obesity
Phase 3 · Investigational

Mechanistic rationale

Native amylin is co-secreted with insulin from pancreatic beta cells and contributes to postprandial satiety, slowed gastric emptying, and glucagon suppression — biology that overlaps with but is mechanistically distinct from GLP-1. The GLP-1-plus-amylin pairing has been the most-discussed pharmacological combination strategy in obesity medicine since the development of cagrilintide gave Novo Nordisk a long-acting amylin agonist suitable for combination dosing.

CagriSema (cagrilintide + semaglutide as a fixed combination) is the most-watched embodiment of this logic, with Phase 3 readouts in obesity and T2D ongoing. Tirzepatide adds the GIP arm to the GLP-1 arm in a single molecule; pairing tirzepatide with an amylin agonist takes the combination logic one step further. Pramlintide is the practical, currently-available amylin analog for users with access to off-label combination.

Human and emerging evidence

The peer-reviewed literature on this combination is summarized below across two tiers — controlled human research (the highest standard) and preclinical / animal-model evidence.

Reported user experiences

Potential benefits and risks

Potential benefits

  • Genuinely complementary mechanisms — GLP-1 and amylin act on different appetite circuits
  • Strong individual-compound evidence, particularly tirzepatide
  • CagriSema Phase 2 data supports the additive concept
  • Practical option for plateau-busting after GLP-1 monotherapy effects level off

Potential risks

  • Combination-specific safety data for tirzepatide + amylin is not yet established
  • Pramlintide requires three-times-daily injection — substantial regimen burden
  • GI tolerability stacks: both classes produce nausea, and combining intensifies it
  • Hypoglycemia risk in patients on insulin or sulfonylureas, particularly with pramlintide
  • Cost and access issues compound when combining two specialty agents

Open questions

  • How does tirzepatide + cagrilintide compare to tirzepatide + pramlintide in head-to-head outcomes?
  • Is the additive weight-loss effect proportional or saturating at higher doses?
  • What are the long-term cardiovascular and renal outcomes of incretin-plus-amylin combinations?
  • Will CagriSema Phase 3 confirm the Phase 2 additive signal at scale?

The takeaway

The GLP-1 + amylin direction is the most evidence-grounded combination strategy in modern obesity pharmacology — genuinely complementary mechanisms, strong per-compound evidence, supportive Phase 2 combination data (CagriSema), and the practical availability of pramlintide for users wanting to explore the logic now. The honest framing: this is one of the more defensible combination concepts on the site, but combination-specific Phase 3 data is still being generated, and the regimen burden (especially with pramlintide's TID injection) is non-trivial.

References

  1. Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2021;398(10317):2160-2172. https://pubmed.ncbi.nlm.nih.gov/34798033/
  2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
  3. Aronne LJ, et al. Pramlintide as an adjunct to lifestyle intervention in the management of obesity. J Clin Endocrinol Metab. 2007;92(8):2977-2983. https://pubmed.ncbi.nlm.nih.gov/17504894/
  4. Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in T2D. Lancet. 2023;402(10403):720-730. https://pubmed.ncbi.nlm.nih.gov/?term=cagrisema